Zenakine

116 days ago

Skinbiotherapeutics – poor trading update and schoolboy accounting blunders

Skinbiotherapeutics (SBTX) later than expected trading update has been poorly received by investors: its not only a revenue miss but howling schoolboy errors by the new FD. This is another management clusterfuck and I shall elaborate n that in a bearcast special shortly.

---

243 days ago

CEOs do not decide the share price, Mr Market does, more cobblers from Stuart Ashman

I despair at the way that there is nobody with PLC experience to stop Skinbiotherapeutics (SBTX) CEO Stuart Ashman from making a complete tit of himself. Today there is another classic.
---